0Y71 Malin Corporation Plc

TIDM0Y71

RNS Number : 6996C

Malin Corporation PLC

13 October 2022

Malin Corporation plc

Closure of Litigation

Dublin-Ireland, 13 October 2022: Malin Corporation plc (Euronext Growth Dublin:MLC) ("Malin", the "Company"), a company investing in highly innovative life sciences companies, gives this update in relation to outstanding litigation.

The Company announced on 13 October 2021 that Irish High Court proceedings had been initiated by the holders of 2,803,801 A Ordinary Shares in the Company ("the Founders") against the Company claiming an entitlement to the conversion of their A Ordinary Shares into Ordinary Shares.

As previously announced, the Company rejected the conversion notices previously submitted to the Company by the Founders, on the basis that no change of control had occurred and the conversion rights carried by A Ordinary Shares were not exercisable.

On 17 August 2022 the Company confirmed that one of the Founders, Crow Rock Capital Limited, the holder of 787,032 A Ordinary Shares, had withdrawn its claim against Malin in those proceedings and surrendered its A Ordinary Shares to the Company.

The Company now confirms that the Company and the remaining Founders have compromised the proceedings, which will be struck out with no order as to costs. The remaining Founders will surrender all of their A Ordinary Shares to the Company, for nil consideration.

On 20 June 2022, the Company announced that defamation proceedings were issued on behalf of Kelly Martin and Sean Murphy against the Company, the Company's Chair, Liam Daniel and the Company's CEO, Darragh Lyons. The Company now confirms that Kelly Martin and Sean Murphy have agreed to discontinue those proceedings.

In consideration of the above agreements, which are in the interests of the Company's shareholders, the Company has agreed to make a EUR1m contribution towards the remaining Founders' costs.

ENDS

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com

For further information contact:

Malin

Fiona Dunlevy, Company Secretary

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

Davy Corporate Finance (Euronext Growth Listing Sponsor & Joint Broker)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

Liberum (Joint Broker)

Phil Walker / Ben Cryer

Tel: +44 (0) 20 3100 2000

Powerscourt (Media enquiries)

Eavan Gannon

Tel: +353 87 236 5973

malin@powerscourt-group.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCELLFFLBLZFBE

(END) Dow Jones Newswires

October 13, 2022 02:00 ET (06:00 GMT)

Malin (LSE:0Y71)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Malin (LSE:0Y71)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024